ARID1A and triple-A syndrome: In the AAA-recipient subgroup, expression of ARID1A was associated with shorter overall survival (OS) (hazard ratio (HR) 10.061; p = 0.033) and disease-specific survival (DSS) (HR 10.061; p = 0.033) (Table S1).